Preclinical and clinical data, though predominantly derived from case reports and small cohort studies to date, consistently indicate that GLP-1 RAs - including liraglutide, semaglutide, and the dual GIP/GLP-1 RA tirzepatide - can induce clinically meaningful weight loss, suppress the characteristic severe hyperphagia, and improve key cardiometabolic parameters in both heterozygous and homozygous MC4R variant carriers
The exclusion was present in the SPD the entire time but wasn't checked
(CMS will still accept applications from state Medicaid agencies.) Here are answers to some questions
The research picture is active and evolving - some studies in different populations have found neutral or even positive bone effects
Lets take a look at each of these factors in more detail, below
Whether oral mazdutide or tirzepatide formulations will emerge remains to be seen